INF 904
Alternative Names: INF-904Latest Information Update: 15 May 2024
At a glance
- Originator InflaRx
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Complement C5a receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Autoimmune disorders; Inflammation
Most Recent Events
- 15 May 2024 INF 904 is available for licensing as of 15 May 2024. https://www.inflarx.de/Home.html
- 21 Mar 2024 InflaRx plans phase IIa trial for Chronic urticaria and Hidradenitis suppurativa in the end of 2024
- 21 Mar 2024 InflaRx plans phase IIb trial for Autoimmune disorders and Inflammation in 2025